• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Economy

ACLX Stock – Get All The Latest Information About It

by September 19, 2024
written by September 19, 2024

ACLX Stock Price, Statistics and Forecast You Need To Know

Have you ever wondered what is the ACLX stock price, and potential over the following years? Why are more and more stock investors interested in the Arcellx Inc. company lately? And why does it seem this stock has great potential?

First of all, to attract more people interested in investing in the Aclx stock, there are some things that any serious investor should consider beforehand. 

It is mandatory to ask yourself – What kind of company are we talking about? What sets that company apart from many others to make its stock worth considering?

Only when you have established all the key things about it is time to deal with their price, statistics, and predictions by experienced experts. Let’s get started with all the basics about this renowned company, shall we?

Arcellx, Inc. – What Is This Company All About?

Arcellx, Inc. (NASDAQ: ACLX) represents a specific biotechnology company that’s been dedicated to advancing human health via innovative cell therapies. They develop extremely cutting-edge immunotherapies with the focus at treating cancer and other incurable diseases. 

Their mission is to create safer treatments that and surely more effective and accessible to a wider range of patients. It’s crucial to note that Arcellx specialises in creating cell therapies targeted at cancers with significant unmet needs. 

Their research and development efforts are concentrated on advancing all of their treatments for the following diseases that are very common nowadays:

Multiple myeloma
Acute myeloid leukemia
Solid tumours
Myelodysplastic syndrome.

What Kind of Technology Do They Use?

This company is known to be using the so-called “D-Domain Technology.” It represents an innovative technology that improves cell therapies. It’s a small, stable, synthetic protein with a special structure.

When used in chimeric antigen receptors (CARs), the D-domain helps cells become more effective at targeting and treating diseases. Its small size makes it easier for the CARs to be inserted into cells and work efficiently.

With this kind of technology, they are able to effectively create a variety of custom proteins that target specific disease markers more precisely. The D-Domain is key to their ddCAR and ARC-SparX platforms. ddCAR platform uses T cells modified to include D-Domain-based CARs designed to seek out and attack specific disease cells.

ACLX Stock News – What Is Happening At The Moment?

Arcellx, Inc. posted a Q2 loss of $0.51 per share, beating the expected $0.54 loss but staying close to last year’s $0.50 loss. This was a 5.56% surprise. Last quarter, the company beat expectations by 72.55%, reporting a $0.14 loss against a $0.51 forecast.

The company earned $27.38 million in revenue for the quarter, missing the estimated 1.23%, though this is up from $14.3 million a year ago. It has exceeded revenue forecasts twice in the past year.

Arcellx’s stock has dropped about 8.3% this year, while the S&P 500 has risen 9%. How the stock performs in the future will depend on future earnings forecasts and what management says next.

Arcellx currently holds a Zacks Rank #3 (Hold). Analysts expect a loss of $0.33 per share on $40.01 million in revenue for the next quarter and a loss of $1.70 on $123.84 million for the full year. The Medical – Biomedical and Genetics sector ranks in the top 37% of industries.

So, before making any investment decisions, let’s look at its statistics and predictions by an expert. Doing comprehensive research is always crucial before investing in any stock! 

Aclx stock price and statistics 

NasdaqGS Real-Time Price Information to note regarding Arcellx Inc. s price and more:

Arcellx Inc. stock Current Price: $70.37 (+$4.91, +7.50%)
Last Updated: September 5, 4:00 PM EDT
Previous Close: $65.46
Open: $65.90
Bid: $70.28 x 200
Ask: $70.56 x 100
Day’s Range: $65.12 – $70.52
52-Week Range: $30.88 – $75.10
Volume: 558,815
Average Volume: 450,216
Market Cap: $3.783 billion
Beta (5-Year Monthly): 0.23
PE Ratio (TTM): Not available
EPS (TTM): -$1.04
Earnings Date: Not announced
Forward Dividend & Yield: Not applicable
Ex-Dividend Date: Not applicable
1-Year Target Estimate: $79.87.

ACLX Stock Forecast by An Expert

If you’re wondering what the ACLX stock 12-Month Forecast is, you should know that it is forecasted to reach an average price of $79.90 over the next 12 months, which is a 13.54% increase from its current price of $70.37. 

This forecast is based on projections from 15 Wall Street analysts. The highest expected price is $85.00, while the lowest is $70.00.

Long-Term ACLX Price Forecast

By 2025: ACLX stock should increase, but specific numbers for 2025 are not provided.
By 2030, The stock could reach approximately $167.27.
By 2035: The average price is expected to be $260.75, with predictions ranging from $252.78 to $263.25, reflecting a +270.54% increase from the current price of $70.37.
By 2040: The forecast suggests an average price of $352.36, with estimates varying between $343.32 and $354.88, showing a +400.72% rise from the current level.
By 2045: The stock is anticipated to average $445.31, ranging from $430.54 to $447.82, indicating a +532.81% change from the current price.
By 2050: The average price could climb to $536.05, with high and low estimates of $537.03 and $519.03, respectively, marking a +661.76% increase from the current level.

Conclusion: Is ACLX Stock A Strong Buy or Not? 

Considering the long-term forecast from our experienced professional, the famous ACLX stock presents considerable growth potential. Our projections indicate significant value increases over the coming years, even decades.

The stock is expected to witness a 13.54% rise next year, with even more solid gains that we anticipate in the long run. Despite this optimistic outlook, investors must weigh the risks and market fluctuations. 

If you’re open to high-risk, high-reward opportunities, ACLX is a compelling buy based on its promising growth trajectory.

The post ACLX Stock – Get All The Latest Information About It appeared first on FinanceBrokerage.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Harris team ‘not aware’ of stolen Trump docs sent ‘directly’ to Biden camp
next post
Amazon increases average pay for warehouse workers and adds free Prime membership perk

related articles

Oil Prices Rebound After Trump’s Criticism of Powell

April 22, 2025

Trump’s Fed Criticism Sparks Investor Concerns

April 22, 2025

Buy Bitcoin Under $100K Before The Next Bull...

April 22, 2025

BNB Price Surge Leads Crypto Gains as Bitcoin...

April 21, 2025

Fed’s Stagflation Warning Impacts Crypto Markets

April 21, 2025

Bitcoin Slips to $83.6K Amid Nvidia’s $5.5B Charge

April 21, 2025

Gold Price Surge Hits $3,385 Amid Trade Tensions

April 21, 2025

Bitcoin Rebounds to $83,404 Amid Renewed Investor Confidence

April 21, 2025

Memecoins, AI, and DeFi Tokens Lead Crypto Rebound

April 21, 2025

Bitcoin Nears $85K Amid Market Optimism

April 21, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Trump blasts Biden’s DOJ: They tried to turn US into a ‘corrupt communist’ third world country

    March 14, 2025
  • Soaring egg prices are threatening a classic holiday tradition: Easter dye kits

    March 1, 2025
  • Biden to meet with national security team ahead of anticipated Iranian attack against Israel

    August 5, 2024
  • Fed rate cuts in September could boost General Motors’ profitability, CFO predicts

    July 23, 2024
  • Long AVGO: leveraging AI-driven growth and strong technical setup for potential breakout towards new highs

    August 14, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (5,783)
  • Investing (634)
  • Stock (893)

Latest Posts

  • John Ratcliffe says US faces ‘most challenging security environment’ ever in confirmation hearing

    January 15, 2025
  • Reddit is attracting ad dollars: will RDDT shares rally further in 2025?

    May 3, 2025
  • Dozens of prominent veterans sign onto letter supporting ‘outstanding’ Hegseth nomination amid controversies

    December 6, 2024

Recent Posts

  • Trump’s approach to Africa lauded by top Republican as recent airstrikes show ‘outside the box’ thinking

    June 18, 2025
  • Dems’ ‘delay tactic’ to ‘malign’ Patel and stall FBI confirmation dismissed as ‘baseless’ by top Senate leader

    February 5, 2025
  • Kroger chairman and CEO resigns following investigation into personal conduct

    March 3, 2025

Editor’s Pick

  • Trump issues ‘last warning’ to Hamas terrorists, demands release of hostages: ‘HELL TO PAY’

    March 6, 2025
  • Thomas Massie says he feels ‘misled’ by Trump after Iran strikes: ‘He’s engaged in war’

    June 22, 2025
  • Trump says Biden ‘is not fit to serve’: ‘Who is going to be running the country for the next 5 months?’

    July 21, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock